JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.
Stocks · News reference
Robotics Remains In Its ‘Lego Era,’ Says Former Nvidia Leader Turned VC as Physical AI Awaits Its ChatGPT Moment
Robotics remains in its Lego era as developers work to improve simulation, safety standards and hardware despite rising investment.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO
The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition.
The Moment Jensen Huang Realized Nvidia 'Won't Have to Die' Came After a Call From This CEO: 'For the Whole Time, 30 Years…'
Nvidia CEO Jensen Huang reveals how repeated calls and a personal letter to TSMC founder Morris Chang forged a decades-long partnership.
1 Obvious Metric That Makes Nvidia a Top Stock to Buy Now
Nvidia's forward P/E ratio suggests significant upside potential as the market has not priced in the company's expected 70% revenue growth for next year. With a forward P/E below 14x compared to its current trailing P/E of 28x, the stock could potentially double by January 2028 if earnings expectations are met and valuation multiples remain stable. Strong demand from AI hyperscalers with locked-in capital expenditure plans supports the growth thesis.
Micron and Sandisk Have a History of Cyclicality. Is This Time Different?
Micron and Sandisk are potentially breaking the cyclical pattern of the memory chip industry by signing long-term contracts with major customers that lock in pricing through 2030-2031. These strategic agreements reduce commodity-like pricing volatility, particularly in DRAM and HBM markets, which could lead to significant stock repricing as investors begin valuing them like regular tech stocks rather than cyclical businesses.